COVID-19
Conditions
Interventions
Nirmatrelvir/ritonavir group:N/A
Azvudine group:N/A
Deuremidevir Hydrobromide(VV116) group:N/A
Simnotrelvir/ritonavir (Xiannuoxin) group:N/A
Leritrelvir (Leruiling) group:N/A
Molnupiravir group:N/A
The untreated small-molecule drug (blank control) group:N/A
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) All patients admitted due to COVID-19 should be included in the study screening. (2) Patients aged over 18 years who are confirmed to have SARS-CoV-2 infection by rapid antigen testing or RT-PCR test upon admission. (3) Patients who receive antiviral treatments such as Paxlovid, Molnupiravir, deute-rimevir hydrobromide, Xuenuoxin, Lairuitewei, and Azvudine during hospitalization, or have not received any antiviral drugs. (4) If the patient has received antiviral treatment within 24 hours before admission, the specific drug should be recorded and the original treatment plan should be continued. (5) Within 24 hours before admission or 48 hours after admission, the first COVID-19 RT-PCR test (including Ct value) was performed, and the Ct value is less than 35.
Exclusion criteria
Exclusion criteria: (1) The patient has only one RT-PCR test during hospitalization. (2) The patient has underlying disease status with high-risk progression factors or virus clearance delay, but cannot receive antiviral treatment due to special reasons. (e.g. organ transplant patients cannot receive antiviral drugs due to strong DDI between some immunosuppressive drugs and Lopinavir/Ritonavir; hemodialysis patients have not received antiviral treatment because they are not included in the treatment population according to the current drug instructions). (3) The patient enters other clinical studies of antiviral drugs for COVID-19 after admission. (4) The patient has received monoclonal antibody drugs for COVID-19 or entered clinical trials related to monoclonal antibody drugs within 3 months before admission. (5) The patient undergoes tracheal intubation within 24 hours after admission and cannot orally take COVID-19 antiviral drugs. (6) The patient has received antiviral treatment within 24 hours before admission, but changed the antiviral treatment plan after admission. (7) The patient has received antiviral treatment for more than 24 hours before admission (e.g. Paxlovid used for =3 times, Azvudine used for =2 times, Remdesivir used for =4 times). (8) The patient receives a two-drug combined antiviral treatment plan for COVID-19 during hospitalization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative conversion time; | — |
Secondary
| Measure | Time frame |
|---|---|
| In-hospital mortality rate;ICU occupancy rate; | — |
Countries
China
Contacts
Public ContactZhongjie Hu
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed